leisure time -WSS

leisure time

author：focus 2025-09-29 13:46:07 - browse：19

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Opioid cravings were reduced by anti

entertainment

explore

WSS

DeSantis can now import cheaper drugs. But will Biden get credit?

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Health and fitness trackers are measuring the wrong things

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Caregivers of transplant patients call for more support, training

As AI regulations shape up, health tech startups beg for clarity

entertainment

leisure time

entertainment

BioMarin wins approval for gene therapy to treat hemophilia A

New menopause drug shows promise in relief for hot flashes

Wildfire smoke exposes gaps in outdoor worker protections

Flagship Pioneering startup Sonata Therapeutics lays off 21

The high cost of giving birth even with insurance

Caregivers of transplant patients call for more support, training

Supreme Court strikes down use of affirmative action

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Hepatitis C has a cure — but many Americans still lack access to it

MD Anderson's Padmanee Sharma responds to research credit suit

hotspot

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

As AI regulations shape up, health tech startups beg for clarity

Flagship Pioneering startup Sonata Therapeutics lays off 21

Designating disabled people as health disparity population is crucial

Readout LOUD podcast: live from JPM 2024

Reporting on presidential health from Reagan to Trump and Biden

entertainment

explore

hotspot

focus